Notch Signaling as a Model to Determine the Function of PS1
About the Research Project
Program
Award Type
Standard
Award Amount
$199,556
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
A1999065
Summary
Mutations in the gene presenilin 1 (PS1) can cause Alzheimer’s disease and result in increased levels of Ab42, a form of APP that causes amyloid plaques. Other data have suggested that PS1 is required for normal APP processing, but the precise function of PS1 in APP processing is unknown. PS1 also appears to be necessary for signaling through the Notch pathway. The Notch pathway begins on the surface of cells, and turning it on is important during embryonic development. The interaction of Notch with PS1 is easier to study than the interaction of PS1 with APP, and Dr. Goate is taking advantage of this fact to better understand the function of PS1. Using the information gained from studying PS1-Notch interactions, she will then be able to ask more informed questions about PS1-APP interactions, and how these interactions are altered in Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD